Bally’s Corporation

Thesis & Rating

Bally’s today is three things stacked on each other, and the stack is the whole story. At the base, a solid US regional casino operator (19 properties across 11 states plus Newcastle UK) throwing off real EBITDAR. On top of it, a transformative October 2025 transaction in which Intralot acquired Bally’s International Interactive for €2.7bn — structured so that BALY emerged controlling the enlarged, Athens-listed Bally’s Intralot (~59%), taking €1.53bn cash and €1.136bn in new Intralot stock, and de-levering the US balance sheet. On top of that, Bally’s Intralot has now agreed to acquire UK-listed Evoke plc (888/William Hill) for ~£243m in stock (52p cash alternative, capped). Wrapped around all of it: Standard General’s ~74% control, three simultaneous mega-projects (the $1.7bn+ Chicago resort, the $4.0bn Bronx integrated resort, the Las Vegas Tropicana site), and ~$4.4bn of long-term debt against an equity stub of ~$660m.

HOLD the situation; we would not own the equity for new money here. There is a real value-investing case — the stub trades at a deep discount to any sum-of-the-parts that credits the casino EBITDAR, the ~59% Intralot stake at market, and the development optionality. But three things keep us off the buy button: (1) control — at ~74% Standard General, minority holders are price-takers on any take-private or related-party step, and the 2024 $18.25 SG buyout (well above today’s price) is the reference for how that asymmetry resolves; (2) leverage & capital intensity — three mega-builds and ~$4.4bn debt mean the equity is a thin, levered call on flawless execution; (3) opacity — consolidating a separately-listed, mid-acquisition subsidiary makes the attributable economics genuinely hard to pin, and we do not pay through for things we cannot cleanly measure. Watch, model the SOTP, and revisit on a control event or a clean post-Evoke pro-forma.

Structure, Segments & Position

Bally’s now reports four segments, and the reporting structure is the most important thing to internalise before looking at any number.

The investable insight: BALY is becoming a holding company whose largest growth engine is a separately listed entity it controls but does not wholly own. Casinos & Resorts is the asset minority holders most cleanly own; the interactive/lottery upside increasingly accrues through the ~59% Intralot stake, where 41% leaks to other shareholders. Bally Bet remains a sub-scale fourth-or-fifth US OSB player — optionality, not a profit center.

Five Forces, Condensed

• ▮Rivalry — mixed by layer. Regional casinos compete locally (elevated pressure flagged in Shreveport, Dover) but enjoy licence-protected catchments; Bally Bet is sub-scale against FanDuel/DraftKings; Intralot B2B competes globally with IGT/Scientific Games-class lottery vendors.
• ▮New entrants — low in casinos (licences), high in interactive. The moat is regulatory and locational, not technological.
• ▮Substitutes — the development bet. Chicago/Bronx/Vegas are bets that destination gaming beats at-home digital; capital-intensive and multi-year.
• ▮Supplier power — landlords literally. Post sale-leasebacks (Lincoln to GLPI; GLPI funding Bronx construction), rent is a senior, fixed claim ahead of the equity.
• ▮Buyer/owner power — the dominant force here is the controlling shareholder. At ~74%, Standard General sets the terms of every structural decision; minorities are along for the ride.

Consolidation & The Evoke Deal

Two industry currents matter: global gaming consolidation (which BALY is now an aggressive vehicle for) and the capital-cost environment for levered builders. The live situation sits on top.

Contained Situation — The Bally’s Intralot / Evoke Acquisition

Announced June 2026: Bally’s Intralot (BALY ~59%) agreed to acquire Evoke plc — owner of 888, William Hill and Mr Green — via a share exchange of 0.537 new Bally’s Intralot shares per Evoke share, valuing Evoke equity at ~£243.1m (at €1.12/BYLOT), with a 52p-per-share cash alternative capped at £117.1m. The cash is backed by a €200m Deutsche Bank/Jefferies bridge; a TPG/Oaktree/OHA steering committee underwrote up to ~£889m of five-year second-lien to refinance Evoke’s 2028 senior debt, plus a £157m senior facility and a £220m revolver, with change-of-control waivers secured on Evoke’s 2030/2031 notes. Completion needs both shareholder bases and regulators, expected Q4 2026–Q1 2027. Read for BALY holders: this is strategically coherent — bolting 888/William Hill’s scale onto the Intralot B2C platform — but it is executed one level down, financed substantially with new debt and new Intralot equity (diluting BALY’s ~59% unless it participates), and it deepens the very holdco opacity that caps the multiple. The strategic logic accrues to “Bally’s Intralot”; the BALY stub gets a diluted, levered, indirect slice. Status: announced, not closed; terms per the 8-K and deal coverage — verify against definitive documents.

Q1 2026 & The Balance Sheet

Q1 2026 (quarter ended 31 March 2026) is the first full quarter consolidating Intralot — revenue jumps, but the path from operating income to the bottom line is where the equity story actually lives.

The honest read: operating businesses make money ($91.6m operating income, even stripping the $105.8m gain leaves the core roughly break-even-to-positive at the EBIT line), but ~$110m/quarter of interest and recurring fair-value/financing noise convert that into a $162m attributable net loss. This is a balance-sheet story wearing an income-statement costume. The equity is the residual after ~$8.6bn of liabilities and ~$1.06bn of NCI — small, levered, and highly sensitive to asset values and rates.

Shape, Not False Precision

We do not publish a precise consolidated EBITDA forecast for a holdco that just absorbed a listed subsidiary and is mid-acquisition of another — false precision would violate house discipline. Instead, the shape:

• ▮FY26: first full consolidated year; revenue step-change to a ~$2.6–3.0bn run-rate as Intralot annualises (ours, from Q1 × mix, not company-guided). Reported net result stays pressured by interest and project pre-opening costs.
• ▮Casinos & Resorts is the stable spine; watch Chicago permanent-facility ramp and competitive pressure in Shreveport/Dover.
• ▮Bally’s Intralot (the ~59% stake) is the growth and the noise: UK B2C strength, lottery B2B contracts, then Evoke on close (Q4’26–Q1’27) — a step-up in scale and leverage one level below BALY.
• ▮Development capital — Chicago + $4.0bn Bronx (with GLPI funding construction; $500m licence fee already paid) + Vegas — is the multi-year swing factor; each is a call option with a cash-burn premium.
• ▮The number that matters is not consolidated EBITDA; it is attributable free cash flow to the BALY stub after interest, rent, NCI leakage and project capital — today thin to negative, by design, during the build phase.

Sum-Of-The-Parts, Not A Point Target

The right lens is sum-of-the-parts on the stub, not a consolidated multiple (which double-counts the 41% of Intralot BALY does not own). Framework, deliberately order-of-magnitude:

• ▮Casinos & Resorts: ~$380m quarterly revenue, ~$96m segment EBITDAR → ~$385m+ annualised EBITDAR; at a regional-casino 6–8× that is ~$2.3–3.1bn EV before property rent capitalisation — the anchor asset.
• ▮~59% of Bally’s Intralot: mark to BYLOT’s Athens market cap × 0.59 (verify live) — a market price exists, so use it rather than estimate.
• ▮Development optionality (Chicago/Bronx/Vegas): real but unquantifiable pre-opening; a wide-range option, net of remaining build capital and the rent stack.
• ▮Less: ~$4.4bn corporate/consolidated debt (careful not to double-count Intralot-level debt against the equity-method value), the rent obligations, and ~$1.06bn NCI.

Run honestly, the parts plausibly exceed the ~$660m equity cap — which is exactly why a control holder finds take-privates attractive at these levels and why minorities should treat the discount as a control-and-leverage discount, not free alpha. Standard General’s 2024 take-private was struck at $18.25/share; today’s ~$13.5 sits well below it, the gap a function of subsequent dilution, debt and project risk — not necessarily a closing arbitrage, since no live take-private offer is on the table. We anchor the rating to the situation and the structure, not to a point price target, consistent with house practice for controlled/special-situation names.

Risk Register & Final Word

• ▮Controlling-shareholder asymmetry (Standard General ~74%) — the defining risk; take-private or related-party terms set without minority leverage.
• ▮Leverage & refinancing — ~$4.4bn debt, rate-sensitive, layered with sale-leaseback rent senior to equity.
• ▮Mega-project execution — Chicago, $4.0bn Bronx, Vegas; overruns or delays hit a thin stub hardest.
• ▮Holdco opacity & NCI leakage — consolidating a ~59% listed subsidiary mid-acquisition obscures attributable economics; ~41% of Intralot upside is not BALY’s.
• ▮Evoke integration & deal risk — announced not closed; financed with new debt/equity a level down; UK regulatory and shareholder approvals outstanding.
• ▮Sub-scale US interactive — Bally Bet is optionality, not a profit center, against entrenched FanDuel/DraftKings.
• ▮Liquidity — ~13m-share effective float makes the listed equity volatile and hard to exit at size.

HOLD — rated to the situation, not a price. New money: AVOID the common until the structure clarifies. Bally’s is a legitimate value-investing puzzle — a sum-of-the-parts that likely exceeds the equity cap — wrapped in three things value investors are right to fear: a ~74% controller who can dictate the exit, a balance sheet carrying ~$4.4bn of debt and three mega-builds, and a consolidation structure that makes the attributable economics genuinely hard to measure. Per Kelly discipline, edge you cannot size is not edge you can bet. We initiate at Hold and revisit on a defined catalyst: a take-private proposal (model the spread to the $18.25 reference then), a clean post-Evoke pro-forma that lets the stub be measured, or a development-milestone de-risking. For exposure to the interactive thesis, the cleaner instrument may be Bally’s Intralot (BYLOT) itself — a separate note.

SOURCES & FLAGS. Q1’26 figures (revenue $755.7m +28.3%; Adj EBITDA ~$153.3m +16.7%; operating income $91.6m incl. $105.8m sale-leaseback gain; net interest $109.9m; other non-op −$145.8m incl. −$104.3m fair-value mark; net loss attributable −$161.9m, EPS −$2.69; LT debt ~$4.39bn; total liabilities ~$8.59bn; NCI ~$1.06bn; segment revenues; $500m NY licence fee) from the Q1’26 10-Q/8-K and release (SEC, BusinessWire, StockTitan, TradingView, affpapa, 18 May–mid-Jun 2026) — press/filing-triangulated, verify against the 10-Q. Intralot reverse-merger: €2.7bn, €1.53bn cash + €1.136bn stock, BALY ~59% of Bally’s Intralot, closed 8 Oct 2025 (BusinessWire/financialcontent). Evoke deal: 0.537 exchange ratio, ~£243.1m equity value, 52p cash alt capped £117.1m, financing syndicate (DB/Jefferies bridge; TPG/Oaktree/OHA second lien up to ~£889m), close Q4’26–Q1’27 (8-K/StockTitan, Jun 2026) — ANNOUNCED, NOT CLOSED; verify against definitive documents. Price ~$13.5 / cap ~$660m / ~48.95m shares (Morningstar 1 Jun $14.08; StockTitan 5 Jun $13.53; WallStreetZen 48,948,795 sh) — effective float small given Standard General ~74% + Hayden ~10% (Wikipedia ownership, dated; verify proxy). Take-private reference $18.25 (2024, SG) from prior coverage memory — verify. TTM net loss ~$701m (StockTitan). FY26 revenue run-rate and SOTP ranges are OUR ESTIMATES / ORDER-OF-MAGNITUDE, not company figures; BYLOT stake should be marked to live Athens price before use. No price target is expressed; rating anchored to structure/situation.

DISCLAIMER. Informational commentary only; not investment advice, an offer, or a solicitation. The Evoke transaction is a disclosed, pending deal; no outcome is assured. USD unless stated.